

2023 YEAR IN REVIEW FOR INVESTOR AUDIENCES

This page is intended for U.S. residents only



Regeneron's co-Founders reflect on 2023 accomplishments.

[JUMP TO OUR MISSION IN MOTION](#)

Forging Our Future Through Scientific Innovation

2023 was another remarkable year of growth through scientific excellence. We brought two new medicines to people in need, advanced numerous possible first- and best-in-class opportunities in our pipeline and steadily grew our business.

We welcomed thousands of new colleagues to our offices around the globe and continued to work together with a science-first mindset to bring vital medicines to people with serious diseases.

[DOWNLOAD OUR 2023 RESPONSIBILITY REPORT](#)

[DOWNLOAD OUR BETTER WORKPLACE, BETTER SCIENCE, BETTER WORLD. IMPACT REPORT](#)

Dear Fellow Shareholders...

Regeneron, at its core, is a company dedicated to the discovery and development of innovative medicines manufactured and commercialized to the highest standards. This approach has established us as a world-class biotechnology company, making a true difference in people's lives. Our ability to create game-changing technologies has disrupted the traditional drug discovery, development, and manufacturing processes, and allows us to continue to push the boundaries of science. Our success can be largely attributed to two factors: our talented team's unwavering dedication to patients and our consistent strategy of investing and reinvesting in the highest quality science, research, and technologies.

Read the full company letter to shareholders in our 2024 Proxy Statement.



2024
Proxy Statement and Notice of Meeting

[DOWNLOAD OUR 2024 PROXY STATEMENT](#)



Leonard S. Schleifer, MD, PhD

Board co-Chair, co-Founder, President and Chief Executive Officer



George D. Yancopoulos, MD, PhD

Board co-Chair, co-Founder, President and Chief Scientific Officer

Regeneron by the Numbers

(as of December 2023)

12

medicines approved in the United States and/or other countries

~35

product candidates in clinical development

6

genetic medicines programs in the clinic

~50

countries with clinical trials

1M+

eligible patients received support from our patient support programs¹

1. Regeneron patient support programs are limited to patients living in the United States and U.S. territories.

~2.3M

exomes sequenced by Regeneron Genetics Center[®]

13.4K+

Regeneron colleagues worldwide at year end

23K+

hours of employee community service through Day for Doing Good (D4DG)

~2.4M

students supported by Regeneron STEM initiatives since 2020

Our Mission in Motion

Dive into Regeneron's journey, hearing straight from colleagues at the forefront of our scientific breakthroughs and responsible business approach.



Our focus on corporate responsibility

2:34



Our focus on genetic medicines

2:13



Our focus on cancer

2:16

Business Snapshot

KEY 2023 FINANCIAL HIGHLIGHTS

- \$13.1B** Total revenue
- \$4.4B** Total R&D investment
- \$2.2B** Total repurchased shares



2023 Annual Reporting Suite



[DOWNLOAD 2024 PROXY STATEMENT](#)



[DOWNLOAD 2023 ANNUAL REPORT](#)



[DOWNLOAD 2023 RESPONSIBILITY REPORT](#)



[DOWNLOAD BETTER WORKPLACE, BETTER SCIENCE, BETTER WORLD. IMPACT REPORT](#)